In this report we describe the reliability of results obtained from approved and laboratory-developed IVD IHC tests assessed by the NordiQC group and consider the potential clinical, economic and socioeconomic impact of inaccurate HER2 test results and subsequent treatment for patients with breast cancer. Here, ERBB2 is linked to breast carcinoma.